secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001159036-22-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q3 revenue $209M (+80% YoY); GAAP EPS $0.44, non-GAAP $0.74
--------------------------------------------------------------------

- Royalty revenue $99.6M (+70% YoY) driven by DARZALEX SC and Phesgo.
- Reiterates FY 2022 revenue guidance $655-685M; non-GAAP EPS $2.10-2.25.
- Completed $720M convertible notes offering; repurchased $200M shares YTD.
- Antares Pharma acquisition contributed product sales; operating income $83.3M.
- Partner milestones: Roche Tecentriq SC met endpoints, argenx BLA for efgartigimod SC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/0001159036-22-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903622000058/halo-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001159036-22-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer